Evaluation of phage therapy in the context of Enterococcus faecalis and its associated diseases

Simple item page
dc.contributor.authorBoloca, Andrei Sorin
dc.contributor.authorUpadrasta, Aditya
dc.contributor.authorde Almeida Bettio, Pedro H.
dc.contributor.authorClooney, Adam G.
dc.contributor.authorDraper, Lorraine A.
dc.contributor.authorRoss, R. Paul
dc.contributor.authorHill, Colin
dc.contributor.funderScience Foundation Irelanden
dc.contributor.funderEuropean Regional Development Funden
dc.contributor.funderJanssen Biotechen
dc.date.accessioned2019-11-20T05:48:52Z
dc.date.available2019-11-20T05:48:52Z
dc.date.issued2019-04-20
dc.description.abstractBacteriophages (phages) or bacterial viruses have been proposed as natural antimicrobial agents to fight against antibiotic-resistant bacteria associated with human infections. Enterococcus faecalis is a gut commensal, which is occasionally found in the mouth and vaginal tract, and does not usually cause clinical problems. However, it can spread to other areas of the body and cause life-threatening infections, such as septicemia, endocarditis, or meningitis, in immunocompromised hosts. Although E. faecalis phage cocktails are not commercially available within the EU or USA, there is an accumulated evidence from in vitro and in vivo studies that have shown phage efficacy, which supports the idea of applying phage therapy to overcome infections associated with E. faecalis. In this review, we discuss the potency of bacteriophages in controlling E. faecalis, in both in vitro and in vivo scenarios. E. faecalis associated bacteriophages were compared at the genome level and an attempt was made to categorize phages with respect to their suitability for therapeutic application, using orthocluster analysis. In addition, E. faecalis phages have been examined for the presence of antibiotic-resistant genes, to ensure their safe use in clinical conditions. Finally, the domain architecture of E. faecalis phage-encoded endolysins are discussed.en
dc.description.statusPeer revieweden
dc.description.versionPublished Versionen
dc.format.mimetypeapplication/pdfen
dc.identifier.articleid366en
dc.identifier.citationBolocan, A.S., Upadrasta, A., Bettio, P.H., Clooney, A.G., Draper, L.A., Ross, R.P. and Hill, C., 2019. Evaluation of phage therapy in the context of Enterococcus faecalis and its associated diseases, Viruses, 11(4), (366). DOI:10.3390/v11040366en
dc.identifier.doi10.3390/v11040366en
dc.identifier.endpage18en
dc.identifier.issn1999-4915
dc.identifier.issued4en
dc.identifier.journaltitleVirusesen
dc.identifier.startpage1en
dc.identifier.urihttps://hdl.handle.net/10468/9140
dc.identifier.volume11en
dc.language.isoenen
dc.publisherMDPIen
dc.relation.projectinfo:eu-repo/grantAgreement/SFI/SFI Research Centres/12/RC/2273/IE/Alimentary Pharmabiotic Centre (APC) - Interfacing Food & Medicine/en
dc.relation.projectinfo:eu-repo/grantAgreement/SFI/SFI Spokes Programme/14/SP APC/B3032/IE/Gut Phageomics - Phage as diagnostics and/or therapeutics in IBD/en
dc.relation.urihttps://www.mdpi.com/1999-4915/11/4/366
dc.rights© 2019 by the authors. Licensee MDPI, Basel, Switzerlanden
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/en
dc.subjectPhage therapyen
dc.subjectE. faecalisen
dc.subjectOrthoMCLen
dc.titleEvaluation of phage therapy in the context of Enterococcus faecalis and its associated diseasesen
dc.typeArticle (peer-reviewed)en
Files
Original bundle
Now showing 1 - 2 of 2
Thumbnail Image
Name:
viruses-11-00366-v2.pdf
Size:
7.61 MB
Format:
Adobe Portable Document Format
Description:
Published version
Download
Thumbnail Image
Name:
viruses-11-00366-s001.pdf
Size:
438.92 KB
Format:
Adobe Portable Document Format
Description:
Published version
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
2.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Microbiology - Journal Articles
APC Microbiome Ireland - Journal Articles